Company intelligence / Profile preview

Toltec Pharmaceuticals

Chicago, Illinois, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~10
Development stage: Phase 2

Overview

Toltec Pharmaceuticals has developed TOL‑463, a novel vaginal anti-infective evaluated in randomized, single-blind Phase 2 controlled trials for the treatment of bacterial vaginosis and vulvovaginal candidiasis. The studies demonstrated safety and efficacy of the product as both a gel and insert. Further research is suggested to assess its role as a biofilm disrupter compared to approved therapies[1][7].

Therapeutic areas: Infectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

TOL-463

Partnerships

National Institute of Allergy and Infectious Diseases (NIAID) – sponsor/collaborator for clinical trials

Beyond the preview

Go deeper on Toltec Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Toltec Pharmaceuticals.

Explore the full profile